Heidelberg Pharma Announces Participation at Various Conferences
Heidelberg Pharma AG today announced that they will present its proprietary ATAC technology at two upcoming scientific events. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.